• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by NewcelX Ltd.

    6/5/26 4:32:07 PM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NCEL alert in real time by email
    6-K 1 ea0293681-01.htm CURRENT REPORT

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    _______________

    FORM 6-K

    _______________

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the Month of June 2026

    Commission File Number: 001-39957

    _______________

    NEWCELX LTD.

    (Translation of registrant’s name into English)

    _______________

    Hohstrasse 1, 8302 Kloten

    Switzerland

    (Address of principal executive office)

    _______________

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

    ☒ Form 20-F            ☐ Form 40-F

     

    CONTENTS

    Attached hereto and incorporated by reference herein is NewcelX Ltd.’s (the “Company”) Notice of Meeting and Proxy Card for the Annual General Shareholders’ Meeting to be held on June 30, 2026 (the “Meeting”). Only shareholders of record who hold common and/or preferred shares of the Company at the close of business on June 5, 2026, will be entitled to vote at the Meeting and any postponement or adjournments thereof.

    This Form 6-K as Exhibit 99.1 is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-282788, 333-268690, 333-269220, 333-295770 and 333-284811), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

    1

    EXHIBIT INDEX

    Exhibit
    Number

     

    Description of Document

    99.1

     

    Notice of Meeting and Proxy Card for the Annual General Shareholders’ Meeting to be held on June 30, 2026.

    2

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    NewcelX Ltd.

    Date: June 5, 2026

     

    By:

     

    /s/ Ronen Twito

       

    Name:

     

    Ronen Twito

       

    Title:

     

    Chief Executive Officer

    3

    Get the next $NCEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NCEL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Samuel Olivier bought $225,000 worth of shares (81,818 units at $2.75) (SEC Form 4)

    4 - NewcelX Ltd. (0001783036) (Issuer)

    4/29/26 4:05:32 PM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CSO and Director Revel Michel bought $149,999 worth of shares (54,545 units at $2.75), increasing direct ownership by 6% to 957,530 units (SEC Form 4)

    4 - NewcelX Ltd. (0001783036) (Issuer)

    4/29/26 4:05:15 PM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by NewcelX Ltd.

    3 - NewcelX Ltd. (0001783036) (Issuer)

    3/18/26 7:04:27 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Samuel Olivier bought $225,000 worth of shares (81,818 units at $2.75) (SEC Form 4)

    4 - NewcelX Ltd. (0001783036) (Issuer)

    4/29/26 4:05:32 PM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CSO and Director Revel Michel bought $149,999 worth of shares (54,545 units at $2.75), increasing direct ownership by 6% to 957,530 units (SEC Form 4)

    4 - NewcelX Ltd. (0001783036) (Issuer)

    4/29/26 4:05:15 PM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

    Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug ("Pre-IND") briefing package to the U.S. Food and Drug Administration ("FDA") to support the proposed First-In-Human ("FIH") clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (("Eledon", NASDAQ:ELDN). The submission represents a significant mi

    5/27/26 7:55:00 AM ET
    $ELDN
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

    NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan

    4/30/26 8:15:00 AM ET
    $ELDN
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

    ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company's strategic collaboration with Eledon Pharmaceuticals (NASDAQ:ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company's development strategy. The updated presentation outlines the integration of NewcelX's scalable stem-cell-derived islet replacement platform with Eledon's investigational anti-CD40L monoclonal antibody tegoprubart, a targ

    4/20/26 7:37:00 AM ET
    $ELDN
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCEL
    SEC Filings

    View All

    SEC Form 6-K filed by NewcelX Ltd.

    6-K - NewcelX Ltd. (0001783036) (Filer)

    6/5/26 4:32:07 PM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by NewcelX Ltd.

    6-K - NewcelX Ltd. (0001783036) (Filer)

    5/27/26 8:00:16 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by NewcelX Ltd.

    EFFECT - NewcelX Ltd. (0001783036) (Filer)

    5/18/26 12:15:18 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCEL
    Leadership Updates

    Live Leadership Updates

    View All

    NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

    ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board ("SAB"). Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap ph

    1/5/26 7:00:00 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

    ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board ("SAB").   Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and

    11/17/25 7:00:00 AM ET
    $NCEL
    $NLSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCEL
    Financials

    Live finance-specific insights

    View All

    NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

    NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan

    4/30/26 8:15:00 AM ET
    $ELDN
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care